PT - JOURNAL ARTICLE AU - Pontes, Gemilson Soares AU - de Melo Silva, Jean AU - Pinheiro-Silva, Renato AU - Barbosa, Anderson Nogueira AU - Santos, Luciano Cardenes AU - de Pádua Quirino Ramalho, Antônio AU - de Castro Alves, Carlos Eduardo AU - da Silva, Danielle Furtado AU - de Oliveira, Leonardo Calheiros AU - da Costa, Allyson Guimarães AU - Bruno, Ana Carla TI - Increased vulnerability to SARS-CoV-2 infection among indigenous peoples living in the urban area of Manaus AID - 10.1101/2021.04.05.21254937 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.05.21254937 4099 - http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254937.short 4100 - http://medrxiv.org/content/early/2021/04/07/2021.04.05.21254937.full AB - Background The COVID-19 pandemic threatens indigenous peoples living in suburban areas of large Brazilian cities and has thus far intensified their pre-existing socio-economic inequalities. This study evaluated the epidemiological situation of SARS-CoV-2 infection among residents of the biggest urban multiethnic indigenous community of the Amazonas state, Brazil.Methods Blood samples of 280 indigenous people who live in the urban community known as Parque das Tribos, which is located in the surrounding area of Manaus, were tested for the presence of anti- SARS-CoV-2 IgA or IgG antibodies using an enzyme-linked immunosorbent assay. An epidemiological standardized interviewer-administered questionnaire was applied to assess the risk factors and sociodemographic information of the study population.Results We found a total positivity rate of 64.64% (95% CI 59.01-70.28) for SARS-CoV-2 infection. IgA and IgG were detected in 55.71% (95% CI 49.89-61.54) and 60.71% (95% CI 54.98-66.45) of the individuals tested, respectively. From the total number (n=280), 80.11% of positive individuals (95%; CI 74.24-85.98) were positive for both IgA and IgG Abs. All individuals with COVID-19-related symptoms on the day of blood collection (n=11) were positive for IgG, while IgA was detected in 84.61% (n=55) of individuals who had presented symptoms several weeks before the blood collection. Individuals aged 30-39 were more susceptible to SARS-CoV-2 infection (prevalence ratio [PR] 0.77; 95% CI 0.58-1.03; p=0.033). People whose main source of information on COVID-19 was religious leaders or friends showed higher susceptibility to infection (PR 1.22; 95% CI 1.00-1.49; p=0.040). In addition, individuals who left home more frequently were at higher risk of infection (PR 1.22; 95% CI 1.00-1.49; p=0.048). Five or more individuals per household increased almost 5-fold the risk of virus transmission (Odds ratio [OR] 2.56; 95% CI; 1.09-6.01; p=0.019). Over 95% of the study population had no access to clean water and/or sanitation.Conclusions The disproportionate dissemination of SARS-CoV-2 infection observed in the Parque das Tribos urban indigenous community might be driven by typical cultural behavior and socioeconomic inequalities. Despite the pandemic threat, this population is not being targeted by public policies and appears to be chronically invisible to the Brazilian authorities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financed in part by the Coordination for the Improvement of Higher Education - CAPES, under Finance code PROCAD AMAZONIA 88881.200581/201801 and Research Support Foundation of Amazonas state (FAPEAM - Pro-Estado Program)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Brazilian Commission for Ethics in Research - CONEP (approval number: 4.260.763)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in the main article or its supplementary information files.